


PHARMACEUTICAL 2019



REGENERON PHARMACEUTICALS INC.

REGENERON

Rank 12 of 371





PHARMACEUTICAL 2019



REGENERON PHARMACEUTICALS INC.



Rank 12 of 371

The relative strengths and weaknesses of REGENERON PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of REGENERON PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 462% points. The greatest weakness of REGENERON PHARMACEUTICALS INC. is the variable Property and Equipment, reducing the Economic Capital Ratio by 7.1% points.

The company's Economic Capital Ratio, given in the ranking table, is 266%, being 597% points above the market average of -331%.

Input Variable	Value in 1000 USD
Assets, Current	6,447,600
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	1,442,800
Liabilities, Non-Current	825,900
Other Assets	2,711,100
Other Compr. Net Income	-6,300
Other Expenses	543,200
Other Liabilities	708,500
Other Net Income	19,100
Property and Equipment	2,575,800
Research and Development	2,186,100
Revenues	6,710,800
Selling, General and Administrative Expense	1,556,200

Output Variable	Value in 1000 USD
Assets	11,734,500
Liabilities	2,977,200
Expenses	4,285,500
Stockholders Equity	8,757,300
Net Income	2,444,400
Comprehensive Net Income	2,441,250
Economic Capital Ratio	266%